Unlocking the Vast Potential of Id Protein Inhibitors

AngioGenex (Ticker: AGGX) is a biopharmaceutical company committed to the discovery and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. AngioGenex and its collaborators, including Robert Benezra, Ph.D., and The Robert Benezra Lab at Sloan Kettering Institute, have assembled key platform enabling technologies and tools that allow for the identification of specific and potent small molecule binders of Id. Id proteins have been shown to play a key role in mediating the pathogenesis of certain cancers and diseases of the eye. AngioGenex’s lead development candidate is AGX-A, a novel small molecule being investigated for the treatment of cholangiocarcinoma (a form of liver cancer) and age-related macular degeneration (AMD). AngioGenex is headquartered in New York, NY.